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Altered KYN/TRP, Gln/Glu, and 
Met/methionine sulfoxide ratios in 
the blood plasma of medication-
free patients with major depressive 
disorder
Hidehiro Umehara1, Shusuke Numata1, Shin-ya Watanabe1, Yutaka Hatakeyama2, Makoto 
Kinoshita1, Yukiko Tomioka1, Kiyoshi Nakahara3, Takeshi Nikawa4 & Tetsuro Ohmori1
Capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) is a comprehensive, 
quantitative, and high throughput tool used to analyze metabolite profiles. In the present study, we 
used CE-TOFMS to profile metabolites found in the blood plasma of 33 medication-free patients with 
major depressive disorder (MDD) and 33 non-psychiatric control subjects. We then investigated changes 
which occurred in the metabolite levels during an 8-week treatment period. The medication-free MDD 
patients and control subjects showed significant differences in their mean levels of 33 metabolites, 
including kynurenine (KYN), glutamate (Glu), glutamine (Gln), methionine sulfoxide, and methionine 
(Met). In particular, the ratios of KYN to tryptophan (TRP), Gln to Glu, and Met to methionine sulfoxide 
were all significantly different between the two groups. Among the 33 metabolites with altered levels in 
MDD patients, the levels of KYN and Gln, as well as the ratio of Gln to Glu, were significantly normalized 
after treatment. Our findings suggest that imbalances in specific metabolite levels may be involved in 
the pathogenesis of MDD, and provide insight into the mechanisms by which antidepressant agents 
work in MDD patients.
Major depressive disorder (MDD) is a common neuropsychiatric disorder with a lifetime prevalence of 16.2%1. 
Although various neurobiological-based hypotheses for the cause of MDD have been proposed2, the molecular 
mechanisms which underlie this disorder remain obscure.
Metabolomics utilizes instruments that can simultaneously quantitate thousands of small molecules in a 
biological sample3. Metabolite levels reflect the final response of an organism to environmental factors, genetic 
modifications, changes in gut microflora, and altered enzyme kinetic activity. Therefore, individual metabolic 
state is most closely related to phenotype among other omics technologies, such as genome, transcriptome, and 
proteome4. Capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) is a comprehensive, quan-
titative, and high throughput tool used to analyze metabolic profiles5–7. To date, CE-TOFMS has been used to 
identify abnormalities of blood metabolites in patients with major depression (MDD), bipolar disorder, schizo-
phrenia, and autism spectrum disorder8–10. However, the study which investigated MDD was conducted in a very 
small cohort of 9 MDD patients and 19 control subjects9.
In the present study, we used CE-TOFMS to comprehensively profile metabolites found in the blood plasma of 
33 medication-free patients with MDD and 33 non-psychiatric control subjects. Next, we examined correlations 
which existed between depression severity and the plasma levels of various metabolites. Finally, we followed the 
patients for 8 weeks to identify any changes which occurred in their metabolite levels.
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Materials and Methods
Subjects. Thirty-three medication-free patients with MDD were recruited from Tokushima University 
Hospital in Japan. The diagnosis of MDD was made according to Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) criteria by at least 2 expert psychiatrists on the basis of extensive clinical interviews and a 
review of medical records. We also followed up 10 patients who received a naturalistic course of treatment with 
an antidepressant (paroxetine n = 4, duloxetine n = 2, mirtazapine n = 1, or sertraline n = 3). Clinical symptoms 
were evaluated using the Hamilton Depression Rating Scale (HDRS) at baseline and again after 8 weeks of treat-
ment11. Thirty-three age- and sex-matched non-psychiatric healthy control subjects were recruited from hospital 
staff, students, and company employees who were documented to be free of psychiatric problems and had no past 
history of mental illness. All participants were of unrelated and of Japanese origin. This study was conducted in 
accordance with the World Medical Association’s Declaration of Helsinki. The study protocol was approved by the 
institutional ethics committee of Tokushima University, and all enrolled subjects provided their signed written 
informed consent for participation.
Quantitative metabolome analysis. A blood sample was collected from each participant during their 
morning visit to the hospital. Blood plasma was isolated via centrifugation at 2,000 g for 10 minutes; after which, 
the plasma-containing supernatant fraction was frozen at −80 °C until further use. 50 μL of plasma sample was 
added to 450 μL of methanol containing 10 μM each internal standard (internal standard solution: H3304-1002; 
Human Metabolome Technologies, Inc.). Then, 200 μL of Milli-Q water and 500 μL chloroform were added, and 
the solution was centrifuged at 2300 g for 5 min at 4 °C. 400 μL of the supernatant was centrifugally filtrated 
through 5-kDa cut-off filter (UltrafreeMC-PLHCC 250/pk, Human Metabolome Technologies) to remove pro-
teins. The filtrate was centrifugally concentrated in a vacuum evaporator and dissolved in 50 μl of Milli-Q water 
containing reference compounds before CE-TOFMS analysis. The levels of various metabolites in the plasma 
samples were measured using a CE-TOFMS system located at Human Metabolome Technologies, Inc. (Yamagata, 
Japan). Target metabolites were identified by matching their mass-to charge ratio (m/z) values and migration 
times with the annotation table of the metabolomic library (Human Metabolome Technologies). The relative 
area for each metabolite was defined as the relative concentration. Details of the procedure of sample preparation 
and the CE-TOFMS conditions and procedures used to analyze the CE-TOFMS data are described elsewhere7–9.
Statistical analyses. Welch’s t-test was used to compare the levels of each metabolite in the MDD group 
with its corresponding level in the control group. A false discovery rate (FDR) correction with a significance 
threshold of 0.05 was applied for multiple testing. Changes which occurred in metabolite levels following treat-
ment with an antidepressant were assessed using a paired t-test. Receiver operating characteristic (ROC) curve 
analyses of candidate metabolites were performed to discriminate between the MDD and control group, and 
values for area under the curve (AUC) were obtained. Spearman’s rank correlation coefficient was used to exam-
ine relationships between metabolite relative concentrations and clinical symptoms as evaluated by the HDRS. 
Statistical calculations of Welch’s t-test, paired t-test, and mean ± standard deviation (SD) were carried out using 
Microsoft Excel 2013 software. ROC curve values and Spearman’s rank correlation coefficients were calculated 
using R ver 3.2.5. software.
Results
Demographics. Some clinical characteristics of the subjects in the two groups are shown in Table 1. There 
were no significant differences regarding the age and sex of the subjects in the the medication-free MDD group 
and control group. Depressive symptoms as evaluated by the HDSR were significantly improved after 8 weeks 
treatment with an antidepressant (mean HDSR score at baseline: 21.0 ± 6.3; mean HDSR score at 8 weeks: 
8.5 ± 5.5, p = 0.007; paired t-test).
Differences in metabolites found in the MDD patients and control subjects. A total of 263 can-
didate peaks (148 cationic compounds and 115 anionic compounds) were detected by CE-TOFMS in our cohort 
of 66 participants. Among the 263 peaks, 246 peaks were assigned to specific metabolites. 246 metabolite relative 
concentrations of each individual subject are shown in Supplementary Table S1. Among these 246 metabolites, 
106 metabolites, which were present in at least 80% of all subjects (≧53 subjects), were analyzed. Among the 
106 metabolites, the levels of 33 metabolites were significantly different in the medication-free MDD group and 
control group (FDR q < 0.05; Welch’s t-test) (Table 2). Among those 33 metabolites, the levels of 11 metabo-
lites were higher in the MDD group than in the control group. For example, decreased levels of kynurenine 
(KYN) and 5-Methoxyindoleacetic acid (5-MIAA), which are associated with tryptophan (TRP) metabolism, 
MDD Control P
N 33 33
Male 10 10
Female 23 23 1
Age 47.1 ± 13.2 46.5 ± 10.1 0.81
HDSR score Baseline 21.0 ± 6.3
8 week 8.5 ± 5.5
Table 1. Demographic of participants. MDD: major depressive disorder; HDRS: Hamilton Depression Rating 
Scale.
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were found in the MDD group (FDR q = 0.0096 and 0.016, respectively). Increased glutamate (Glu) levels and 
decreased glutamine (Gln) levels were found in the MDD group (FDR q = 3.7 × 10−7 and 4.8 × 10−7, respectively) 
(Fig. 1). This was deemed important, because both Glu and Gln are associated with glutamatergic neurotransmis-
sion. Furthermore, the ratios of KYN to TRP, Gln to Glu, and methionine (Met) to methionine sulfoxide in the 
MDD group were lower than those in the control group (p = 5.4 × 10−4, 1.3 × 10−13, and 5.6 × 10−12, respectively) 
(Table 3).
Next, we performed ROC analyses to examine the power of metabolite relative concentrations to diagnose 
MDD. An AUC value for each metabolite relative concentration is shown in Table 2. Methionine sulfoxide, 
an oxidation product of methionine and a possible biomarker of oxidative stress12, was able to discriminate 
medication-free MDD patients from the control subjects, and showed the best AUC among 35 metabolites exam-
ined (AUC = 0.97, sensitivity 0.91, and specificity 0.97).
Relationship between metabolite relative concentrations and depressive symptoms. We 
examined relationships between the relative concentrations of 106 metabolites and the depressive symptoms 
of the MDD patients as evaluated by their HDSR scores. We found nominally positive correlations between the 
relative concentrations of 6 metabolites (isoleucine, leucine, 2-hydroxybutyric acid, valine, 3-hydroxybutyric acid, 
and 2-aminoadipic acid) and HDSR scores (r = 0.593, r = 0.473, r = 0.421, r = 0.448, r = 0.424, r = 0.367, and 
r = 0.354, respectively; p < 0.05; Spearman rank correlations). However, only the correlation between a patient’s 
isoleucine relative concentration and their symptoms reached statistical significance when assessed by multiple 
comparisons (FDR q < 0.05).
Compound name
Control (N = 33) Medication-free MDD (N = 33)
Medication-free (N = 33) vs 
Control (N = 33)
Mean 
relative area S.D. N
Mean 
relative area S.D. N p value
FDR q 
value
AUC 
value
Cystine 0.0041 0.0016 33 0.0014 0.00096 33 2.7E-11 2.9E-09 0.96
Glutamate (Glu) 0.021 0.0061 33 0.061 0.03 33 6.9E-09 3.7E-07 0.94
Glutamine (Gln) 0.097 0.018 33 0.057 0.029 33 1.5E-08 4.8E-07 0.89
Asparate (Asp) 0.0017 0.00038 33 0.0037 0.0016 33 1.8E-08 4.8E-07 0.91
Inosine monophosphate 
(IMP) 0.00037 0.0002 32 0.00011 0.000079 25 2.9E-08 6.1E-07 0.93
O-Acetylcarnitine 0.01 0.0021 33 0.0058 0.0036 33 5.6E-08 9.9E-07 0.86
Methionine sulfoxide 0.00049 0.00015 33 0.0028 0.0021 33 5.7E-07 8.6E-06 0.97
3-Phosphoglyceric acid 0.00055 0.00022 33 0.00028 0.00014 23 1.4E-06 1.9E-05 0.84
Isocitric acid 0.0017 0.00037 33 0.0012 0.00041 32 1.1E-05 1.3E-04 0.81
Asparagine (Asn) 0.0086 0.0015 33 0.0063 0.0023 33 1.8E-05 1.9E-04 0.82
Uridine 0.0011 0.00018 33 0.00092 0.00015 33 4.3E-05 4.1E-04 0.77
Phosphorylcholine 0.00029 0.000097 32 0.00044 0.00017 33 5.3E-05 4.7E-04 0.78
Glyceric acid 0.0011 0.00041 33 0.0018 0.00081 33 3.6E-04 0.0029 0.76
Hypoxanthine 0.0031 0.0023 33 0.0012 0.0019 31 4.9E-04 0.0035 0.86
5-Oxoproline 0.0032 0.0006 33 0.0056 0.0035 33 5.3E-04 0.0035 0.74
Methionine (Met) 0.0037 0.00077 33 0.0024 0.0017 27 5.5E-04 0.0035 0.79
Uric acid 0.022 0.0044 33 0.018 0.0056 33 5.6E-04 0.0035 0.73
2-Hydroxybutyric acid 0.003 0.001 33 0.0046 0.0025 33 0.001 0.0056 0.74
cis-Aconitic acid 0.0025 0.00053 32 0.002 0.0006 33 0.001 0.0056 0.71
Creatinine 0.018 0.0032 33 0.016 0.0028 33 0.002 0.0096 0.71
Hippuric acid 0.00064 0.00063 32 0.00025 0.00022 30 0.002 0.0096 0.77
Kynurenine 0.00048 0.00012 33 0.00039 0.0001 33 0.002 0.0096 0.73
S-Methylcysteine 0.00081 0.00031 33 0.00057 0.0003 29 0.003 0.013 0.69
Thiaproline 0.00052 0.00014 32 0.00037 0.00021 32 0.003 0.013 0.73
1-Methyladenosine 0.000059 0.000012 33 0.000049 0.000013 33 0.004 0.016 0.71
5-Methoxyindoleacetic acid 
(5-MIAA) 0.00013 0.000041 33 0.0001 0.000036 33 0.004 0.016 0.70
Glycerophosphocholine 0.0018 0.00084 33 0.0044 0.0046 33 0.004 0.016 0.63
Glucose 6-phosphate 0.00024 0.00012 33 0.00017 0.000082 28 0.005 0.019 0.71
2-Aminoisobutyric acid 0.0054 0.0014 33 0.0067 0.0022 33 0.009 0.032 0.68
N-Methylnorsalsolinol 0.000085 0.000031 33 0.00011 0.000039 31 0.009 0.032 0.68
Ethanolamine 0.0013 0.00025 33 0.0011 0.00032 33 0.012 0.040 0.70
Threonic acid 0.0023 0.00062 33 0.0029 0.001 33 0.012 0.040 0.65
Isethionic acid 0.0002 0.000063 33 0.00017 0.000028 33 0.014 0.045 0.61
Table 2. Differences in metabolites in the medication-free MDD patients and control subjects.
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Metabolite changes following 8 weeks of treatment with antidepressants. Among the 33 metab-
olites that displayed altered levels in medication-free MDD patients, only two metabolites (Gln and KYN) showed 
significant changes in their levels after 8 weeks of treatment with antidepressants (Table 4). The levels of both Gln 
and KYN were significantly increased after treatment (p = 3.3 × 10−4 and 3.8 × 10−3, respectively; paired-t test). 
Furthermore, the ratio of Gln to Glu was also significantly increased after treatment (p = 6.6 × 10−4). While the 
KYN to TRP ratio was increased to its control level after treatment, the increase did not reach statistically signifi-
cance (p = 0.074). On the other hand, the Met to methionine sulfoxide ratio remained unchanged after treatment 
(p = 0.61).
Figure 1. Plasma amino acid levels in medication-free patients with major depressive disorder (MDD) and 
controls. Y axis represents relative metabolic levels. Bars indicate mean levels in the group. (a) Kynurenine 
were significantly lower in MDD patients than in control subjects (FDR q = 0.0096). (b) The levels of 
5-Methoxyindoleacetic acid were significantly lower in MDD patients than in control subjects (FDR q = 0.016). 
(c) Glutamate levels were significantly higher in MDD patients than in control subjects (FDR q = 3.7 × 10−7). 
(d) Glutamine levels were significantly lower in MDD patients than in control subjects (FDR q = 4.8 × 10−7).
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Discussion
In this study, we used CE-TOFMS to comprehensively profile the metabolites found in blood plasma from 
medication-free MDD patients and control subjects, and identified novel differential metabolites as well as imbal-
ances of specific metabolite in the plasma of medication-free MDD patients. An organism’s metabolite levels are 
regarded as its final response to environmental factors, which include treatment with medications. Moreover, 
several studies have demonstrated that antidepressants influence the levels of certain metabolites13, 14. Therefore, 
we analyzed samples of blood plasma obtained from medication-free MDD patients in an attempt to identify a 
Ratio
Control (N = 33)
Medication-free 
MDD (N = 33)
MDD before 
treatment (N = 10)
MDD after 8 weeks 
treatment (N = 10)
Medication-
free (N = 33) vs 
Control (N = 33)
Before (N = 10) 
vs After (N = 10) 
in MDD
Mean 
relative 
area S.D.
Mean 
relative 
area S.D.
Mean 
relative 
area S.D.
Mean 
relative 
area S.D. p value p value
KYN/TRP 0.031 0.007 0.026 0.005 0.027 0.006 0.031 0.005 5.4E-04 0.074
Glutamine/Glutamate 4.99 1.37 1.5 1.59 1.71 1.57 2.32 1.6 1.3E-13 6.6E-04
Methionine/Methionine sulfoxide 8.13 2.92 2.33 2.19 3.11 2.59 3.86 4.78 5.6E-12 0.61
Table 3. Ratios of metabolites in control subjects and MDD patients before and after antidepressant treatment.
Compound name
Medication-free MDD 
(N = 10)
MDD after 8 weeks 
treatment (N = 10)
Before (N = 10) vs After 
(N = 10) in MDD
Medication-on MDD 
(N = 10) vs CTRL (N = 33)
Mean 
relative area S.D.
Mean 
relative area S.D. p value p value
Glutamine (Gln) 0.063 0.033 0.085 0.029 3.3E-04 0.25
Kynurenine 0.00042 0.00011 0.00052 0.000095 0.0038 0.23
Uridine 0.00086 0.0001 0.00097 0.00016 0.082 0.047
Hypoxanthine 0.0011 0.0019 0.0026 0.0041 0.087 0.73
3-Phosphoglyceric acid 0.00041 0.00021 0.00036 0.00021 0.092 0.061
Glycerophosphocholine 0.0034 0.0034 0.0013 0.00057 0.1 0.063
Inosine monophosphate (IMP) 0.00012 0.000056 0.00007 0.000021 0.15 7.3E-10
Glutamate (Glu) 0.056 0.025 0.046 0.016 0.16 6.2E-04
Asparate (Asp) 0.0039 0.0011 0.0034 0.0013 0.16 0.0022
Methionine sulfoxide 0.002 0.0019 0.0025 0.0022 0.21 0.021
Creatinine 0.015 0.0033 0.016 0.0027 0.23 0.081
5-Methoxyindoleacetic acid 
(5-MIAA) 0.00012 0.000041 0.00014 0.000058 0.23 0.5
Glyceric acid 0.0014 0.0005 0.0012 0.00051 0.23 0.89
5-Oxoproline 0.0068 0.0046 0.0052 0.0016 0.24 0.0042
1-Methyladenosine 0.000052 0.000015 0.000058 0.0000085 0.26 0.87
Asparagine (Asn) 0.0072 0.003 0.0079 0.0023 0.31 0.38
Methionine (Met) 0.0027 0.0021 0.0032 0.0024 0.36 0.57
Hippuric acid 0.00024 0.00016 0.00033 0.00019 0.4 0.022
Uric acid 0.019 0.0047 0.02 0.0041 0.4 0.14
Threonic acid 0.0026 0.0007 0.0024 0.00074 0.4 0.69
Ethanolamine 0.0013 0.0004 0.0013 0.0004 0.52 0.98
2-Aminobutyric acid 0.0066 0.0028 0.0061 0.0024 0.54 0.39
N-Methylnorsalsolinol 0.00012 0.000041 0.00011 0.000045 0.61 0.11
2-Hydroxybutyric acid 0.0048 0.003 0.0043 0.0029 0.65 0.17
Isethionic acid 0.00016 0.000034 0.00018 0.000067 0.67 0.39
Phosphorylcholine 0.0004 0.00017 0.00038 0.000095 0.74 0.03
Cystine 0.0015 0.001 0.0016 0.0009 0.76 1.1E-06
S-Methylcysteine 0.00067 0.00022 0.00063 0.0003 0.87 0.13
Thiaproline 0.00041 0.00021 0.0004 0.00017 0.92 0.083
Isocitric acid 0.0015 0.0005 0.0015 0.0004 0.92 0.18
O-Acetylcarnitine 0.0066 0.0029 0.0067 0.0025 0.93 0.0011
cis-Aconitic acid 0.0023 0.0005 0.0023 0.00047 0.95 0.33
Glucose 6-phosphate 0.00017 0.000087 0.00017 0.0001 0.98 0.26
Table 4. The changes in metabolites in the MDD patients after 8 weeks of antidepressant treatment.
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precise metabolite signature for MDD. Furthermore, we conducted a longitudinal study which examined changes 
in metabolite abnormalities that occurred after treating MDD patients with antidepressants.
We found that plasma from medication-free MDD patients contained significantly decreased levels of Gln, 
increased levels of Glu, and had an altered Gln/Glu ratio. However, the abnormal Gln levels and Gln/Glu ratio 
became significantly normalized after 8 weeks of treatment with antidepressants. In a glutamatergic synapse, the 
released neurotransmitter is internalized by astrocytes through high affinity sodium-dependent glutamate trans-
porters, and then transformed into Gln by the astrocyte-specific enzyme, glutamine synthetase, and released into 
the extracellular space, from which it is taken up into neurons through the neutral amino acid transporter and 
transformed back to Glu by phosphate-activated glutaminase15. The complete series of steps from neuronal glu-
tamate release to resynthesis of glutamate from glutamine is called the Glu-Gln cycle16, and the Gln/Glu ratio is 
regarded as a potentially useful index for Glu-Gln cycle in neuronal-glial interactions and the balance of glutama-
tergic metabolites17–19. The abnormal Gln and Glu levels and Gln/Glu ratio found in MDD patients in this study 
suggest that abnormalities in the Glu-Gln cycle may be involved in the pathogenesis of MDD. Consistent with 
our results, elevated blood Glu levels in MDD patients20–24 as well as decreased plasma Gln in drug-naive MDD 
patients have been reported25. In the current study, the plasma Gln levels in MDD patients were increased after 
treatment with antidepressants, while the plasma Glu levels following treatment remained unchanged. However, 
results from other studies have suggested that antidepressant agents might decrease plasma Glu levels in MDD 
patients24, 26. When taken together, the above findings suggest that antidepressant agents may normalize glutama-
tergic abnormalities by increasing Gln levels and decreasing Glu levels.
We found significantly decreased levels of KYN and 5-MIAA, as well as significantly altered KYN/TRP ratio in 
the plasma samples from medication-free MDD patients. The abnormal KYN levels were significantly normalized 
following 8 weeks of treatment with antidepressants. Serotonin is synthesized from ~1% of the available TRP in the 
body, and TRP is catabolized into KYN by tryptophan 2,3-dioxygenase27. 5-MIAA is metabolite formed within the 
methoxyindole branch of the TRP pathway. The abnormalities of KYN, 5-MIAA, and the KYN/TRP ratio found in 
this study implicate disruption of the TRP pathway in the pathogenesis of MDD. Consistent with our results, a pre-
vious study which used liquid-chromatography-tandem mass spectrometry (LC-MSMS) has reported decreased 
serum KYN levels in drug-free MDD patients28. However, conflicting results have also been reported29, 30. 
These discrepancies between studies may primarily result from whether their respective patient populations 
received medications, as we found elevated plasma KYN levels and a trend towards elevated KYN/TRP ratio after 
the patients in our study had been treated with antidepressants. Previous studies have reported elevated serum 
KYN levels and KYN/TRP ratio during the course of antidepressant treatment in MDD patients31, 32.
We found significantly increased levels of methionine sulfoxide, decreased levels of Met, and altered Met/
methionine sulfoxide ratio in samples of blood plasma collected from medication-free MDD patients. The abnor-
mal levels of methionine sulfoxide and Met and the abnormal ration of these two metabolites did not significantly 
change after 8 weeks of treatment with antidepressants. Met is a sulfur-containing essential amino acid, and is 
used as the first amino acid during the protein translation process. As a result, Met is often a limiting factor for 
protein synthesis under conditions of Met deficiency33. Met also participates in one-carbon metabolism, and 
decreased levels of Met may be associated with aberrant DNA methylation in MDD34. Methionine sulfoxide is 
a primary oxidation product of Met via its nucleophilic oxidation, and this amino acid can be regarded as a bio-
marker of oxidative stress12. Accumulating evidence implicates oxidative stress in the pathogenesis of MDD35, 36. 
Consistent with our findings, a previous study showed that a 6-week course of antidepressant treatment did not 
alter the oxidative-antioxidative systems in MDD patients37. However, several clinical studies have shown the 
efficacy of adjunctive treatment with the antioxidant compound, N-acetylcysteine, in MDD patients38, 39.
We found a significant positive correlation between isoleucine relative concentration and depression sever-
ity. Isoleucine is one of branched-chain amino acids (BCAAs), and this amino acid is transported across the 
blood-brain barrier as nutrient signals and nitrogen donors in neurotransmitter synthesis and Glu-Gln cycle40. 
Consistent with our findings, depressive-like symptoms in rats following chronic administration of BCAAs41 and 
an association between plasma isoleucine concentration and the severity of MDD have been observed42. On the 
other hand, decreased blood concentrations of BCAAs in patients with MDD treated with antidepressants in 
comparison with healthy controls and negative correlations between BCAAs concentrations and the severity of 
MDD have also been reported43.
When we compared with our data of MDD with a previous blood study of bipolar disorder using 
CE-TOFMS10, increased Glu levels and decreased cis-Aconitic acid levels, which is an intermediate product of 
the citric acid cycle, have been commonly observed between studies. These results suggest that not only glutama-
tergic abnormalities but also abnormalities in the citric acid cycle may be commonly involved in the pathogenesis 
of mood disorders.
Our study has several limitations that should be mentioned. First, the sample size was relatively small, and 
larger studies are needed to confirm our results. Second, the patients were not all treated with the same antide-
pressants. Thus further studies which use specific treatment protocols are required. Third, we examined metab-
olite levels in samples of peripheral blood gathered from MDD patients. However, those metabolite levels may 
not have reflected the status of metabolites in the brain tissue of those MDD patients. On the other hand, some 
of the altered plasma metabolites described in the present study have also been identified in samples of brain tis-
sues and cerebrospinal fluid (CSF). For example, a postmortem study has revealed increased Glu levels in MDD 
patients44. Moreover, proton magnetic resonance spectroscopy (1HMRS) studies have demonstrated reduced Gln 
levels in the hippocampus and pregenual anterior cingulate cortex of unmedicated MDD patients, as well as 
increased Glu levels in the occipital cortex region45–47. Furthermore, abnormality of the Gln/Glu ratio in the 
CSF of MDD patients and impaired Glu-Gln cycle in the brains of depressed patients have been observed19, 48. 
A high-performance liquid chromatography study has also revealed reduced ethanolamine levels in the CSF of 
MDD patients49. Fourth, we did not take potential confounding factors, such as body mass index and smoking 
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status into consideration in our analysis due to lack of these information. Finally, the blood samples used in our 
study were collected when the patients visited the hospital in the morning; therefore, the interval between final 
food intake and blood draw was not unified, and we cannot rule out that food consumption and drinking may 
have affected the metabolite levels.
In conclusion, we described specific metabolite signatures that were found in samples of blood plasma 
obtained from medication-free MDD patients. We also conducted a longitudinal study that identified changes 
which occurred in those signatures after the patients had been treated with antidepressants. Our results suggest 
that imbalances of specific metabolites may be involved in the pathogenesis of MDD, and provide insight into the 
mechanisms by which antidepressants affect MDD.
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